Table 1 Baseline demographics and disease characteristics of all patients, those who did not receive SCT, and those who proceeded to maintenance

From: Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

  Total (N = 65) Patients who did not proceed to SCT (N = 42) Patients who received maintenance (N = 25)
Median age, years (range) 66 (34–86) 68 (34–86) 69 (34–77)
 Age ≥65 years, n (%) 34 (52) 26 (62) 16 (64)
 Age ≥75 years, n (%) 12 (18) 10 (24) 4 (16)
Male, n (%) 36 (55) 23 (55) 14 (56)
Race, n (%)
  White 52 (80) 33 (79) 18 (72)
  Black or African American 12 (18) 8 (19) 6 (24)
  Asian 1 (2) 1 (2) 1 (4)
ISS disease stage at diagnosis, n (%)
  I 28 (43) 17 (40) 14 (56)
  II 28 (43) 18 (43) 10 (40)
  III 9 (14) 7 (17) 1 (4)
MM subtype, n (%)
  IgG 44 (68) 27 (64) 15 (60)
  IgA 14 (22) 10 (24) 5 (20)
  IgD 1 (2) 1 (2) 1 (4)
  Light chain 6 (9) 4 (10) 4 (16)
 Median creatinine clearance, mL/min (range) 81.4 (27.8–167.2) 77.0 (28.0–167.0) 79.0 (46.0–167.0)
 High-risk cytogenetic abnormalitiesa, n (%) 5 (8) 3 (7) 2 (8)
  del 17 2 (3) 1 (3) 1 (4)
  t(4;14) 1 (2) 1 (3) 0
  t(14;16) 2 (3) 2 (5) 1 (4)
  1. ISS International Staging System, MM multiple myeloma, SCT stem cell transplantation
  2. aHigh-risk cytogenetic abnormalities included: del 17/17p, t(4;14), and/or t(14;16) detected by fluorescence in situ hybridization or metaphase cytogenetics